Pharmaceutical MDL-2804 Actively Recruiting Northern District of Ohio

National Opioid Litigation

The largest public health litigation in U.S. history. Cities, counties, states, and tribes are suing opioid manufacturers, distributors, and pharmacy chains for fueling the opioid epidemic that has claimed over 800,000 American lives since 1999.

Last Updated: June 1, 2026
12 min read
JPML Data Verified
6 sources cited

Key Takeaways

  • $50+ billion in total settlements to states and localities
  • The largest public health litigation in U.S. history
  • Over 800,000 Americans have died from opioid overdoses since 1999
  • Purdue/Sackler settlement of $7 billion confirmed November 2025
  • Settlements paid over 18-year period to fund treatment and prevention
$50B+
Total Settlements
800K+
Opioid Deaths (1999-2023)
2,930
Pending Actions
18 yrs
Settlement Payout Period

Key Facts (June 2026)

Pending Actions 2,930 cases in federal MDL
Total Settlements $50+ billion to states and localities
Distributor Settlement $21 billion (McKesson, Cardinal, AmerisourceBergen)
Purdue/Sackler Settlement $7 billion (confirmed November 2025)
Pharmacy Settlements $13+ billion (CVS, Walgreens, Walmart)
Primary Plaintiffs Cities, counties, states, tribes (NOT individuals)
MDL Consolidated December 2017
Presiding Judge Hon. Dan Aaron Polster (N.D. Ohio)
Fund Usage Requirement 85%+ must fund opioid abatement
Status Actively Recruiting (new cases accepted)

Case Tracking - 2025-2026

With major settlements in place, case count has stabilized with a slight -2% decline as claims are resolved. Most governmental plaintiffs have joined settlement agreements.

Jan 25
2,994
Feb 25
2,994
Mar 25
2,994
Apr 25
2,985
May 25
2,985
Jun 25
2,985
Jul 25
2,985
Aug 25
2,982
Sep 25
2,982
Oct 25
2,965
Nov 25
2,965
Dec 25
2,965
Jan 26
2,964
Feb 26
2,957
Mar 26
2,957
Apr 26
2,941
May 26
2,932
Jun 26
2,930

Source: JPML MDL Statistics Reports, January 2025-June 2026

1 What Is This Litigation?

The National Prescription Opiate Litigation (MDL-2804) is a massive consolidation of lawsuits filed by cities, counties, states, and Native American tribes against the companies they allege caused and profited from the opioid epidemic.

This is NOT Individual Injury Litigation

Unlike most MDLs, this litigation is primarily governmental—plaintiffs are local and state governments seeking to recover public costs incurred responding to the opioid crisis: emergency services, healthcare, law enforcement, social services, and more. Individual overdose victims and their families generally are not part of this MDL.

Defendants include drug manufacturers (Purdue Pharma, Johnson & Johnson, Teva), the "Big Three" distributors (McKesson, Cardinal Health, AmerisourceBergen), and major pharmacy chains (CVS, Walgreens, Walmart). Collectively, over $50 billion in settlements have been reached.

2 The Opioid Crisis: Three Waves

Wave 1 1990s-2010

Prescription Opioid Deaths

Increased prescribing of opioids began in the 1990s, driven by campaigns minimizing addiction risks. Opioid prescribing increased fourfold from 1999-2010, paralleled by a fourfold increase in overdose deaths.

Wave 2 2010+

Heroin Deaths

As prescription opioids became harder to obtain, many users transitioned to heroin. Heroin overdose deaths increased rapidly starting in 2010, though they have declined in recent years (down 33% from 2022-2023).

Wave 3 2013+

Synthetic Opioid Deaths (Fentanyl)

Illegally manufactured fentanyl (50-100x more potent than morphine) has saturated the drug supply. Fentanyl is now the leading cause of opioid deaths, often found in counterfeit pills or mixed with other drugs.

806K+
Deaths (1999-2023)
217
Deaths/Day (2023)
5.7M
With OUD (2023)
-24.5%
Deaths (2024-25)

Source: CDC, NIDA. OUD = Opioid Use Disorder

3 The Defendants

M Manufacturers

Purdue Pharma (OxyContin) $7B settlement

Developed OxyContin in 1995. Alleged aggressive marketing downplaying addiction risks. Filed bankruptcy 2019, settlement confirmed November 2025.

Johnson & Johnson $5B settlement

Manufactured opioids through Janssen; supplied ingredients through Noramco. Ceased opioid sales 2020.

Teva Pharmaceutical $4.5B+ settlement

Major generic opioid manufacturer. Settlement includes $1.2B in generic Narcan (naloxone).

Allergan $2B settlement

Opioid manufacturer; agreed to settlement provisions over 7 years.

D Distributors ("Big Three")

Combined Settlement $21B

Paid over 18 years. Required to create clearinghouse to detect and report suspicious opioid orders.

McKesson
Cardinal Health
AmerisourceBergen
(now Cencora)

Alleged to have failed "suspicious order monitoring" obligations—shipping massive quantities to pharmacies despite clear red flags.

P Pharmacy Chains

Walgreens $5.52B (15 years)
CVS Health $4.90B (10 years)
Walmart $2.74B (6 years)

Alleged to have filled prescriptions from "pill mills" and failed to train pharmacists to identify red flags.

4 The $50+ Billion in Settlements

Defendant(s) Amount Timeline
Distributors (McKesson, Cardinal, Cencora) $21B 18 years
Purdue Pharma / Sackler Family $7B Confirmed Nov 2025
Walgreens $5.52B 15 years
Johnson & Johnson $5B 9 years
CVS Health $4.90B 10 years
Teva (cash + Narcan) $4.5B+ 13 years
Walmart $2.74B 6 years
Allergan $2.02B 7 years
TOTAL $50B+
85% Abatement Requirement: At least 85% of settlement funds going to states and localities must be used for opioid crisis abatement—treatment, harm reduction, prevention, and related services.

5 How Settlement Funds Must Be Used

Treatment & Recovery

  • • Medication-assisted treatment (MAT)
  • • Substance use disorder facilities
  • • Recovery support services
  • • Treatment for pregnant women with OUD

Harm Reduction

  • • Naloxone (Narcan) distribution
  • • Syringe services programs
  • • Fentanyl test strip distribution
  • • Overdose prevention education

Prevention Programs

  • • Youth prevention education
  • • Prescriber training
  • • Public awareness campaigns
  • • Early intervention services

Criminal Justice

  • • Drug courts
  • • Diversion programs
  • • Jail-based treatment
  • • Reentry support services

6 Who Are the Plaintiffs?

Cities, Counties & Municipalities

The vast majority of plaintiffs are local governments seeking to recover costs from emergency services, healthcare, law enforcement, foster care, and social services strained by the opioid crisis.

States (Often Separate from MDL)

Many states filed independent litigation through their Attorneys General, pursuing separate settlements. State claims may be coordinated with but distinct from the federal MDL.

Native American Tribes

Federally recognized tribes have filed claims alleging disproportionate impact on tribal communities. Tribal claims are not settled by the national settlement agreements.

Hospital Systems & Insurers

Healthcare providers and insurers have filed claims seeking to recover treatment costs and payments made for opioid prescriptions.

NOT Individual Victims: The national settlements do NOT resolve claims by private individuals, families of overdose victims, private hospitals, or private insurers. These parties may have separate legal options.

7 Frequently Asked Questions

Can individuals sue for opioid-related injuries?
MDL-2804 is primarily for governmental plaintiffs. Individual personal injury claims are generally not part of this MDL and would be handled separately in state courts. If you or a family member suffered opioid-related harm, consult with an attorney about your specific options.
Where is the settlement money going?
Funds are distributed to states and local governments. At least 85% must be used for opioid abatement—treatment programs, harm reduction (like naloxone distribution), prevention, and recovery services. Johns Hopkins Bloomberg School of Public Health tracks spending through their National Settlement Fund Tracking Project.
Why is the MDL still "actively recruiting"?
Not all potential plaintiffs have filed claims. New defendants (like pharmacy benefit managers) are being added. Some jurisdictions are newly filing, and appeals may return cases to the MDL. Litigation against pharmacy chains continues for entities that didn't join national settlements.
What happened to Purdue Pharma and the Sacklers?
Purdue Pharma filed for bankruptcy in 2019. After years of litigation, a settlement plan providing up to $7 billion for opioid abatement was confirmed by the bankruptcy court in November 2025. The Sackler family contributed to this settlement while receiving certain legal protections.
Are opioids still being prescribed?
Yes, opioids remain important for pain management, but prescribing has declined significantly. The 2016 and 2022 CDC guidelines recommend opioids be reserved for severe pain when alternatives are inadequate. Prescription monitoring programs (PDMPs) now operate in all 50 states to prevent misuse.
Is the opioid crisis getting better?
There are signs of improvement. Overdose deaths declined 4% from 2022-2023 (the first annual decline since 2018), and preliminary 2024-25 data shows a 24.5% decline. However, fentanyl remains a major threat, and approximately 217 people still die daily from opioid overdoses.

Sources & References

6 official sources cited

Judicial Panel on Multidistrict Litigation (JPML) — Official MDL statistics

CDC Overdose Prevention — Opioid crisis statistics and three waves

NIDA — Opioid classification and research

National Opioid Settlement — Settlement details and allocations

Johns Hopkins Opioid Principles — Settlement fund tracking

CDC Clinical Practice Guideline for Prescribing Opioids, 2022. Data current as of June 2026.

Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.

Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.

Read our full disclaimer · Privacy Policy · Terms of Use